Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
959.9 USD | -0.47% | -0.47% | +9.29% |
Mar. 18 | US appeals court revives Regeneron's antitrust lawsuit against Novartis | RE |
Mar. 18 | US appeals court revives Regeneron's antitrust lawsuit against Novartis | RE |
Business Summary
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Number of employees: 13,450
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medicines
100.0
%
| 12,173 | 100.0 % | 13,117 | 100.0 % | +7.76% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
51.5
%
| 6,821 | 56.0 % | 6,754 | 51.5 % | -0.98% |
Rest of World
44.4
%
| 4,987 | 41.0 % | 5,827 | 44.4 % | +16.85% |
Other
4.1
%
| 365 | 3.0 % | 536 | 4.1 % | +46.84% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 64 | 88-01-07 | |
Chief Executive Officer | 71 | 88-01-07 | |
Director of Finance/CFO | 54 | 02-12-31 | |
Melissa Lozner
CMP | Compliance Officer | - | 21-12-31 |
Bob McCowan
CTO | Chief Tech/Sci/R&D Officer | - | - |
Andrew Murphy
CTO | Chief Tech/Sci/R&D Officer | 66 | 98-12-31 |
Neil Stahl
CTO | Chief Tech/Sci/R&D Officer | 67 | 90-12-31 |
Patrice Gilooly
COO | Chief Operating Officer | - | 97-12-31 |
Chief Tech/Sci/R&D Officer | - | 18-12-31 | |
Mark Hudson
IRO | Public Communications Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Christine Poon
BRD | Director/Board Member | 71 | 10-11-11 |
Chief Executive Officer | 71 | 88-01-07 | |
Michael Brown
BRD | Director/Board Member | 82 | 91-05-31 |
Joseph Goldstein
BRD | Director/Board Member | 83 | 91-05-31 |
George Sing
BRD | Director/Board Member | 74 | 88-01-07 |
Founder | 64 | 88-01-07 | |
Arthur Ryan
BRD | Director/Board Member | 81 | 02-12-31 |
N. Coles
BRD | Director/Board Member | 63 | 17-02-16 |
David Schenkein
BRD | Director/Board Member | 66 | 23-09-07 |
Bonnie Bassler
BRD | Director/Board Member | 61 | 16-09-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 10 | 1,818,146 | 0 | 0 | 77.18 % |
Stock B | 1 | 133,443,750 | 104,398,850 ( 78.23 %) | 25,500,000 ( 19.11 %) |
Company contact information
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
10591-6707, Tarrytown
+914 847 7000
http://www.regeneron.comGroup companies
Name | Category and Sector |
---|---|
Regeneron Ireland DAC
Regeneron Ireland DAC BiotechnologyHealth Technology Part of Regeneron Pharmaceuticals, Inc., Regeneron Ireland DAC is a leading Irish biotechnology company that uses science to develop new medicines for patients. The private company is located in Ireland. The company successfully manufactures a range of biopharmaceuticals for patients worldwide, including approved therapeutic proteins and those involved in clinical studies. |
Biotechnology
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.29% | 104B | |
+1.10% | 105B | |
-3.00% | 22.09B | |
-11.89% | 21.98B | |
-26.59% | 20.17B | |
-5.20% | 19.49B | |
-6.58% | 17.75B | |
+5.83% | 13.84B | |
+7.46% | 11.64B | |
+28.56% | 11.55B |
- Stock
- Equities
- Stock Regeneron Pharmaceuticals, Inc. - Nasdaq
- Company Regeneron Pharmaceuticals, Inc.